Actions
Pages
Subscribe for newsletter
Stories
Tokenized real-world assets (RWAs) represent tangible and intangible assets, from real estate to government bonds, that have traditionally been a part of the conventional financial system. As these RWAs transition to the blockchain, they are shaping the future of finance. In a bullish forecast, 21.co, a leading digital asset firm, projects a potential $10 trillion market by 2030.
Real World Assets anchor immense global wealth. With the convergence of traditional finance and cryptocurrency markets, tokenized RWAs offer enhanced efficiency, liquidity, and the exciting potential to democratize wealth opportunities for all. While there are regulatory and technological nuances to navigate, the potential for widespread adoption is immense and promising.
“This trend is expected to result in exponential growth in the tokenized RWA industry, particularly as more liquidity flows into the space. This will lead to a more sustainable bull market with less capital flight at its peak.” - Matthijs de Vries, co-founder of AllianceBlock.
The world moves from digital where there is less friction to physical where things are not as easy to read/write. The first industry to undergo a change in RWA will likely be the next frontier of digital assets such as internet connectivity and telco services which are a natural forward point after electronic currency (mobile phone airtime is already used as a quasi currency all over the world). We will be looking toward companies involved in crypto enabled telco services. Expect an influx of institutional investors, a more regulated environment, and new platforms that simplify the tokenization process. Integration of tokenized assets into everyday financial products and services is on the horizon.
The tokenization of real-world assets isn't just about numbers and forecasts. It represents a paradigm shift in how we view ownership, investment, and wealth distribution. As digital dollars pave the way, other assets like government bonds, real estate, and even art are joining the fray, signaling a future where digital and tangible worlds seamlessly coexist.
Real-world assets, ranging from real estate to government bonds, are being integrated onto the blockchain. With Ethereum leading the pack in tokenized assets, boasting over 6 million daily users. The realm of tokenized real estate, valued at $613 trillion in 2023, is particularly noteworthy, with a 102% growth in on-chain real estate between Q1 and Q3 2023. The growth of tokenized U.S. government bonds, in particular, reflects the increasing trust and acceptance of this digital transition.
Two platforms to keep an eye on are https://metablox.io/ which is working in the digital realm of RWA. Centrifuge https://centrifuge.io/ is a bridge between RWA and blockchains, tokenizing assets to allow for the creation of lending markets using those assets.
Cryptocurrency and Blockchain Integration
Story
Sanofi (Nasdaq: $SNY), a multinational pharmaceutical and healthcare company, in a strategic move towards becoming a frontrunner in AI-powered drug discovery, invests $10 million in California-based BioMap. This collaboration aims to leverage BioMap's cutting-edge AI engine, turning data sets into a biological map of proteins, advancing drug discovery across immunology, neurology, oncology, and rare diseases.
The partnership highlights the convergence of Biotech and Tech and validates that AI has important industry applications beyond consumer tech. Sanofi's commitment to being the first pharmaceutical company powered by AI at scale gains momentum with this collaboration. The partnership with BioMap aligns with Sanofi's broader strategy to harness AI and data science capabilities, optimizing the discovery and development of groundbreaking biotherapeutics.
"By combining Sanofi’s proprietary data sets, digital infrastructure, AI, and data science capabilities with BioMap’s AI engine, we can optimize the process of discovery and development of breakthrough biotherapeutics." - Matt Truppo, Sanofi’s Global Head of Research Platforms.
The collaboration marks a significant step towards Sanofi's ambition to lead in AI-driven pharmaceuticals. The partnership sets the stage for transformative advancements in drug discovery, hinting at a future where AI plays a pivotal role in optimizing treatment development.
In the broader landscape of AI-driven advancements, Sanofi's strategic collaborations with Exscientia, Atomwise, Insilico, and Owkin form a cohesive tapestry, positioning the pharmaceutical giant at the forefront of AI innovation. Committing over $2 billion total to these companies, this multifaceted approach is integral to Sanofi's vision of becoming the inaugural pharmaceutical company powered by artificial intelligence at scale.
In the broader context of AI's transformative influence on the landscape of pharmaceuticals, Google DeepMind's Alphafold stands as a groundbreaking example. Recently acclaimed for predicting protein structures with remarkable accuracy, Alphafold exemplifies the prowess of AI methodologies in understanding complex biological systems.
As Sanofi assembles an extensive AI toolkit through collaborations, DeepMind's success with Alphafold serves as a testament to the potential of AI in unraveling intricate biological processes. This synergy between Sanofi's collaborations and breakthroughs like Alphafold heralds a new era where AI is not just a tool but a transformative force in the sector.
Pharmaceuticals, AI-driven Drug Discovery
Story
Genesis Therapeutics harnesses AI in a landmark $200 million funding round, highlighting a pivotal moment for AI-enabled drug development and the biotech sector's rapid growth.
The substantial investment in Genesis underscores a broader confidence in AI's role in pioneering advanced drug discovery and development, signaling a potential shift in traditional biotech strategies. This evolution is not just theoretical; it's now entering a practical, critical stage with real-world impacts.
"AI presents a potent opportunity to revolutionize the drug discovery process," said CEO Dr. Evan Feinberg. "This funding comes as Genesis is approaching an inflection point with the first of our AI-enabled drug candidates entering the clinic."
The industry anticipates the forthcoming clinical trials of Genesis' AI-enabled drug candidates, marking a significant milestone in AI's practical application in biotech. Success here could catalyze a larger shift toward technology-driven approaches in the sector.
This development is part of a larger trend. Companies like Mana.bio are also merging AI with biotech for drug development, emphasizing the growing importance of technology in this field. Despite external challenges, such as recent attacks in Israel impacting Mana.bio’s operations, these companies remain steadfast in their missions, showing the resilience and urgency of innovation in this space.
Biotech & Artificial Intelligence
Story
Innovators
Scroll
Open
Close